AKT1 and acute lymphoblastic leukemia: In addition, numerous pathway inhibitors, such as GDC-0941 (a pan class I PI3K inhibitor), MK-2206 (an allosteric Akt inhibitor), RAD001 (an mTORC1 inhibitor) and the dual PI3K/PDK1 inhibitors NVP-BAG956 and NVP-BEZ235, show a potent cytotoxic effect in T-ALL cell lines, as well as in patient-derived cells [112].